BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — August 13, 2026

India BSE PHARMA

By Gunpowder Editorial ·

5 high priority 12 medium priority 17 total filings analysed

Executive Summary

The 17 filings from S&P BSE PHARMA constituents for August 13, 2026, reveal a sector bifurcated between strong top-line growth and margin pressures. IPCA Laboratories and Aurobindo Pharma delivered standout performances, with revenue surging 21% YoY and 16% YoY respectively, alongside significant EBITDA margin expansion (IPCA +344 bps standalone, Aurobindo maintaining >21% margins).

In contrast, Max Healthcare Institute reported a mixed quarter: gross revenue grew 16% YoY but PAT rose only 3% YoY, with EBITDA margins contracting 100 bps QoQ to 24.8%, driven by rising costs from acquisitions and capex. The sector saw no insider trading activity in this batch, but capital allocation trends were evident—Max Healthcare approved ₹425 Cr brownfield expansion and granted stock options, while Aurobindo incorporated a new WOS for global manufacturing. Forward-looking data from Aurobindo (double-digit revenue guidance, >21% EBITDA margins) and scheduled AGMs for Glenmark (Sept 11, dividend ₹2.50/share) and GSK (postal ballot for director appointments) provide near-term catalysts. Dr. Reddy's senior management departure (CEO of API & Services) and IPCA's amalgamation of Krebs Biochemicals add strategic dimensions. Overall, the theme is 'growth with discipline'—companies with strong product mix and cost control (IPCA, Aurobindo) are outperforming those with acquisition-related drags (Max Healthcare).

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance · Company update · M&A

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from August 12, 2026.

Investment Signals (10)

  • IPCA Laboratories ↓ (BULLISH)
    ▲

    Consolidated revenue grew 20.8% YoY to ₹2,788 Cr, net profit surged 80% YoY to ₹423 Cr, and standalone EBITDA margin expanded 245 bps YoY to 26.27%. Export income grew 34% YoY.

  • Aurobindo Pharma ↓ (BULLISH)
    ▲

    Q1 FY27 consolidated revenue up 16% YoY to ₹9,150 Cr, operating EBITDA margin at 21% (ex-one-time), with reiterated FY27 guidance of double-digit revenue growth and EBITDA margins above 21%. US business launched 10 new products.

  • Max Healthcare Institute ↓
    ▲

    Gross revenue grew 16% YoY to ₹2,982 Cr and Network Operating EBITDA up 15% YoY to ₹704 Cr, but PAT grew only 3% YoY to ₹357 Cr and EBITDA margin contracted 100 bps QoQ to 24.8%. Acquisition-related costs and rising expenses (professional fees +22.7% YoY, finance costs +29.4% YoY) are pressuring profitability. [MIXED/BEARISH]

  • IPCA Laboratories ↓ (BULLISH)
    ▲

    Standalone net profit surged 42% YoY to ₹373 Cr, with EBITDA margin improving to 26.27% from 23.82% YoY. The amalgamation of Krebs Biochemicals could unlock synergies.

  • Aurobindo Pharma ↓ (BULLISH)
    ▲

    Completed Lannett acquisition and doubled China OSD production, indicating aggressive global expansion. Formulation business contributed 89% of revenues, with US business filing 9 ANDAs and receiving 10 final approvals.

  • Max Healthcare Institute ↓ (BULLISH)
    ▲

    International patient revenue grew 18% YoY to ₹247 Cr (~9% of hospital revenue), Max Lab revenue grew 20% YoY to ₹58 Cr, and Max@Home revenue grew 32% YoY to ₹78 Cr—showing strong ancillary growth.

  • Dr. Reddy's Laboratories ↓ (BEARISH)
    ▲

    Resignation of CEO of API and Services (Deepak Sapra) effective Nov 12, 2026, with no replacement announced—creates leadership vacuum in a key business segment.

  • Glenmark Pharmaceuticals ↓
    ▲

    Recommended dividend of ₹2.50/share for FY26, with AGM on Sept 11, 2026—consistent shareholder return policy. [NEUTRAL/BULLISH]

  • Max Healthcare Institute ↓ (BULLISH)
    ▲

    Granted 3,61,827 stock options under ESOP 2022 with exercise prices of ₹800 and ₹350, aligning employee interests with long-term value creation.

  • IPCA Laboratories ↓ (BULLISH)
    ▲

    Consolidated basic EPS (before exceptional items) jumped to ₹15.84 from ₹9.19 YoY, reflecting strong earnings growth.

Risk Flags (8)

  • Max Healthcare/Margin Compression↓ [HIGH RISK]
    ▼

    EBITDA margin contracted to 24.8% from 26.8% QoQ and 24.9% YoY. Total expenses grew 18.4% YoY, outpacing revenue growth of 16.7%. Finance costs surged 29.4% YoY and depreciation rose 26.4% YoY.

  • Max Healthcare/Net Debt Increase↓ [MODERATE RISK]
    ▼

    Net debt rose to ₹2,384 Cr from ₹1,908 Cr in March 2026 (+25%), driven by acquisitions (Kalinga Hospital, Yerawada Properties) and ₹425 Cr capex approval.

  • Dr. Reddy's/Key Personnel Departure↓ [MODERATE RISK]
    ▼

    CEO of API and Services (Deepak Sapra) resigning effective Nov 12, 2026, with no successor named—could disrupt API business, a key growth driver.

  • Aurobindo Pharma/Tax Rate Headwind↓ [MODERATE RISK]
    ▼

    Net tax rate elevated at 31.9% due to not taking tax credits on loss-making subsidiaries, potentially depressing net profit growth despite strong operational performance.

  • Max Healthcare/Standalone Underperformance↓ [HIGH RISK]
    ▼

    Standalone revenue grew only 12.8% YoY and standalone PAT grew just 0.9% YoY, significantly lagging consolidated growth (16.7% revenue, 4.9% PAT). Acquisition-driven growth may mask organic weakness.

  • IPCA Laboratories/Other Income Decline↓ [LOW RISK]
    ▼

    Standalone other income declined 30% YoY and consolidated other income declined 23% YoY, reducing overall profitability cushion.

  • Max Healthcare/Sequential Revenue Decline↓ [MODERATE RISK]
    ▼

    Consolidated revenue declined ~7% QoQ and PAT fell ~5% QoQ vs Q4 FY26, indicating potential seasonality or integration challenges.

  • Aurobindo Pharma/ARV Flatness↓ [LOW RISK]
    ▼

    ARV formulation revenue remained flat at $35 million, indicating stagnation in a key therapeutic segment.

Opportunities (10)

  • IPCA Laboratories/Margin Expansion↓ (OPPORTUNITY)
    ◆

    Standalone EBITDA margin improved to 26.27% from 23.82% YoY (+245 bps), and consolidated margin improved to 22.88% from 18.39% YoY (+449 bps). If sustained, this could drive significant EPS upgrades.

  • Aurobindo Pharma/Guidance Reiteration↓ (OPPORTUNITY)
    ◆

    Management reiterated FY27 guidance of double-digit revenue growth and EBITDA margins above 21%, providing visibility. US business momentum (10 new launches, 9 ANDAs filed) supports this.

  • Max Healthcare/Ancillary Growth Engines↓ (OPPORTUNITY)
    ◆

    Max Lab (+20% YoY), Max@Home (+32% YoY), and international patients (+18% YoY) are growing faster than core hospital revenue, offering diversification and higher-margin revenue streams.

  • IPCA Laboratories/Export Growth↓ (OPPORTUNITY)
    ◆

    Standalone export income grew 34% YoY to ₹935 Cr, indicating strong demand in regulated markets. This could be a sustainable growth driver.

  • Aurobindo Pharma/Lannett Acquisition↓ (OPPORTUNITY)
    ◆

    Completed acquisition adds scale in US generics, with potential cost synergies and market share gains.

  • Max Healthcare/Brownfield Expansion↓ (OPPORTUNITY)
    ◆

    ₹425 Cr capex for new hospital block at Vaishali (brownfield) typically has faster payback and higher ROI than greenfield projects.

  • Glenmark Pharmaceuticals/Dividend Capture↓ (OPPORTUNITY)
    ◆

    Record date for ₹2.50/share dividend is August 31, 2026. Investors seeking yield can buy before this date.

  • IPCA Laboratories/Amalgamation Synergies↓ (OPPORTUNITY)
    ◆

    Merger with Krebs Biochemicals (appointed date April 1, 2026) could create vertical integration benefits and cost savings in the API segment.

  • Aurobindo Pharma/China OSD Doubling↓ (OPPORTUNITY)
    ◆

    Doubling China OSD production capacity opens access to a large, growing market with potential for high-volume, low-cost manufacturing.

  • Max Healthcare/ESOP Grant↓ (OPPORTUNITY)
    ◆

    Grant of 3,61,827 options at exercise prices of ₹800 and ₹350 (current market price likely higher) aligns management incentives with shareholder value creation.

Sector Themes (5)

  • Revenue Growth vs Margin Divergence
    ◆

    3/3 major companies (IPCA, Aurobindo, Max Healthcare) reported double-digit revenue growth (16-21% YoY), but margin trends diverged sharply—IPCA and Aurobindo expanded margins, while Max Healthcare saw compression. Companies with strong product mix (IPCA's exports, Aurobindo's US generics) are better positioned. [IMPLICATION: Favor companies with high-margin product portfolios over acquisition-heavy growth strategies.]

  • Acquisition-Driven Growth with Integration Risks
    ◆

    Max Healthcare completed two acquisitions (Kalinga Hospital, Yerawada Properties) in Q1 FY27, which boosted consolidated revenue but added debt (net debt +25% QoQ) and dragged margins. Aurobindo's Lannett acquisition is still in early integration. [IMPLICATION: Monitor integration timelines and cost synergies; near-term margin pressure is likely for acquisitive companies.]

  • Capital Allocation Shift Toward Expansion
    ◆

    Max Healthcare approved ₹425 Cr brownfield capex and granted stock options, while Aurobindo incorporated a new WOS for global manufacturing. IPCA's amalgamation of Krebs Biochemicals indicates consolidation. [IMPLICATION: Companies are prioritizing growth capex over shareholder returns (dividends/buybacks) in this cycle.]

  • Leadership Changes Creating Uncertainty
    ◆

    Dr. Reddy's senior management departure (CEO of API & Services) without a named successor adds uncertainty to a key business segment. Max Healthcare also saw resignation of its Chief Procurement Officer. [IMPLICATION: Leadership transitions in critical roles can disrupt operations; monitor for succession announcements.]

  • Regulatory and Procedural Filings Dominate
    ◆

    10/17 filings were routine procedural (AGM notices, postal ballots, ESOP grants, analyst call availability) with low materiality. This suggests a quiet period between earnings seasons, with most actionable data concentrated in quarterly results. [IMPLICATION: Focus on the 7 filings with financial data for investment decisions; the rest are noise.]

Watch List (8)

  • Glenmark Pharmaceuticals/AGM↓
    👁

    AGM on Sept 11, 2026, with dividend record date Aug 31, 2026. Watch for any strategic updates or guidance changes during the meeting. [Date: Sept 11, 2026]

  • GlaxoSmithKline Pharmaceuticals/Postal Ballot↓
    👁

    E-voting for appointment of Ms. Karine J F Natland as Non-Executive Director and re-appointment of MD Bhushan Akshikar runs Aug 14 to Sept 13, 2026. Results by Sept 15. [Date: Sept 15, 2026]

  • Dr. Reddy's Laboratories/Successor Announcement↓
    👁

    Resignation of CEO of API and Services effective Nov 12, 2026. Watch for announcement of replacement and any strategic changes in API business. [Date: Before Nov 12, 2026]

  • Max Healthcare/Integration Progress↓
    👁

    Monitor Q2 FY27 results for margin recovery and debt reduction from Kalinga Hospital and Yerawada Properties acquisitions. Capex execution at Vaishali also key. [Date: Q2 FY27 results expected Oct 2026]

  • IPCA Laboratories/Amalgamation Approvals↓
    👁

    Merger with Krebs Biochemicals requires consents/approvals. Watch for regulatory clearances and timeline updates. [Date: Ongoing]

  • Aurobindo Pharma/Lannett Synergies↓
    👁

    Q2 FY27 results will provide first full quarter of Lannett contribution. Watch for margin impact and synergy realization. [Date: Q2 FY27 results expected Oct/Nov 2026]

  • Aurobindo Pharma/Tax Rate Normalization↓
    👁

    Elevated tax rate of 31.9% due to loss-making subsidiaries. Watch for any improvement as subsidiaries turn profitable or tax credits are utilized. [Date: Ongoing]

  • Max Healthcare/ESOP Vesting↓
    👁

    3,61,827 options granted with vesting period 1-5 years. Watch for any insider selling patterns post-vesting as a signal of management sentiment. [Date: Starting Aug 2027]

Filing Analyses (17)
IPCA Laboratories Limited Corporate Governance positive materiality 8/10

13-08-2026

Ipca Laboratories Limited reported consolidated revenue from operations of ₹2,788.10 crore for Q1 FY27 (quarter ended June 30, 2026), representing a 20.8% increase year-over-year from ₹2,308.85 crore in Q1 FY26. Standalone revenue grew 21.3% YoY to ₹2,119.24 crore. All figures are unaudited and accompanied by an unmodified review report. However, while revenue and profit grew significantly, the company recorded a negative other comprehensive income of ₹20.08 crore at the consolidated level, and the standalone net profit margin remained relatively flat sequentially (17.6% vs 17.2% in Q4 FY26).

  • · The Board approved the amalgamation of Krebs Biochemicals & Industries Ltd. with the Company with appointed date April 1, 2026, pending consents/approvals.
  • · Exceptional item of ₹30.42 crore in Q4 FY26 (full year) relates to the impact of new Labour Codes on gratuity and leave liability.
  • · Consolidated basic EPS (before exceptional items) for Q1 FY27 stood at ₹15.84, up from ₹9.19 in Q1 FY26.
  • · Standalone basic EPS (before exceptional items) for Q1 FY27 was ₹14.71, up from ₹10.33 in Q1 FY26.
  • · The company operates in a single operating segment: Pharmaceuticals.
Max Healthcare Institute Limited Market Notice mixed materiality 8/10

13-08-2026

Max Healthcare Institute reported Q1 FY27 gross revenue of ₹ 2,982 Cr, up 16% YoY, and Network Operating EBITDA of ₹ 704 Cr, up 15% YoY. However, PAT growth was modest at 3% YoY to ₹ 357 Cr, and EBITDA margin contracted slightly to 24.8% from 24.9% in Q1 FY26 and 26.8% in Q4 FY26. The company completed two strategic acquisitions (Kalinga Hospital and Yerawada Properties) and approved a ₹ 425 Cr brownfield expansion, while net debt increased to ₹ 2,384 Cr from ₹ 1,908 Cr in March 2026.

  • · Max Lab gross revenue grew 20% YoY and 11% QoQ to ₹ 58 Cr, with services in 60+ cities and 2,700+ tests.
  • · Max@Home gross revenue grew 32% YoY and 7% QoQ to ₹ 78 Cr.
  • · International patient revenue grew 18% YoY to ₹ 247 Cr, accounting for ~9% of hospital revenue.
  • · Bed occupancy was 75% in Q1 FY27, with OBDs up 10% YoY.
  • · Operational bed capacity increased by 630 beds (net) YoY to 5,379 beds.
  • · Free cash from operations declined 31.7% QoQ to ₹ 397 Cr from ₹ 581 Cr in Q4 FY26.
  • · Net debt increased 24.9% from March 2026 to ₹ 2,384 Cr, driven by acquisitions and capex.
  • · Kalinga Hospital acquisition cost was ~₹ 298 Cr, funded through External Commercial Borrowing.
  • · MSSH Bhubaneswar contributed ₹ 19 Cr revenue and ~₹ 2 Cr EBITDA in the post-acquisition period, with 50% occupancy and ARPOB of ₹ 35k.
  • · YPPL acquisition gives 100% voting rights and ~50.22% economic interest; Class B shares to be acquired progressively.
  • · 202 beds at Max Smart Super Speciality Hospital operationalized; 198 more to be handed over in Q2 FY27.
  • · Board approved ₹ 425 Cr capex for a 202-bed brownfield tower at MSSH Vaishali, expected commissioning in Q4 FY30.
  • · Board granted in-principle approval to set up medical colleges in view of proposed NMC regulatory changes.
  • · Free treatment provided to 54,186 OPD and 1,933 IPD patients from economically weaker sections.
  • · Clinical achievements include ~4,683 liver transplants, ~5,988 kidney transplants, and ~2,289 bone marrow transplants performed till date.
  • · Published 123 articles in high impact journals; 120 clinical trials and 25 grant studies ongoing.
  • · 610+ MBBS doctors in DNB programmes across 40 specialities; 1,000+ new students enrolled in online courses.
Max Healthcare Institute Limited Market Notice mixed materiality 8/10

13-08-2026

Max Healthcare Institute Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026, reporting profit after tax of ₹32,296 lakhs (₹323.0 Cr), up 4.9% YoY from ₹30,797 lakhs (₹308.0 Cr) in Q1 FY25. Revenue from operations grew 16.7% YoY to ₹2,36,617 lakhs (₹2,366 Cr). The board also approved a ₹425 Crore capital expenditure for a new hospital block at Max Super Speciality Hospital, Vaishali, and appointed two senior executives while accepting the resignation of Dr. N. Venkatesan, Senior Director & Chief Procurement Officer.

  • · Q1 FY26 total expenses rose 18.4% YoY to ₹1,97,038 lakhs (from ₹1,66,365 lakhs), outpacing revenue growth partly due to higher purchase of drugs (+19.3%), professional fees (+22.7%), finance costs (+29.4%) and depreciation (+26.4%).
  • · Other income declined 15.3% YoY to ₹4,052 lakhs (from ₹4,783 lakhs in Q1 FY25).
  • · Exceptional items in FY26 full year amounted to ₹4,824 lakhs (none in Q1 or Q4 FY26).
  • · Three subsidiaries (unaudited) had nil revenues and a combined net loss of ₹330 lakhs for the quarter.
  • · Paid-up equity share capital increased sequentially from ₹97,313 lakhs (March 31, 2026) to ₹97,324 lakhs.
  • · The company added two new subsidiaries during Q1: Kalinga Hospital Limited (May 18) and Yerawada Properties Private Limited (June 30).
Max Healthcare Institute Limited Market Update mixed materiality 8/10

13-08-2026

Max Healthcare Institute Limited reported consolidated revenue from operations of ₹2,36,617 lakh for Q1 FY27 (quarter ended June 30, 2026), up 16.7% YoY from ₹2,02,757 lakh in Q1 FY26, while consolidated profit after tax rose 4.9% YoY to ₹32,296 lakh from ₹30,797 lakh. The quarter included the consolidation of Kalinga Hospital Ltd (acquired May 18, 2026) and Yerawada Properties (acquired June 30, 2026), which added revenues but also finance costs and one-time items. However, standalone revenue grew only 12.8% YoY and standalone PAT grew just 0.9% YoY, reflecting a slower standalone performance compared to the consolidated growth.

  • · Consolidated total income for Q1 FY27 was ₹2,40,669 lakh, up from ₹2,06,408 lakh in Q1 FY26.
  • · Consolidated profit before exceptional items and tax for Q1 FY27 was ₹43,631 lakh, up from ₹40,043 lakh in Q1 FY26.
  • · Consolidated total comprehensive income for Q1 FY27 was ₹31,815 lakh, up from ₹30,516 lakh in Q1 FY26.
  • · Standalone total income for Q1 FY27 was ₹87,502 lakh, up from ₹77,387 lakh in Q1 FY26.
  • · Standalone profit before exceptional items and tax for Q1 FY27 was ₹22,591 lakh, up from ₹22,280 lakh in Q1 FY26.
  • · Standalone total comprehensive income for Q1 FY27 was ₹16,325 lakh, down from ₹16,466 lakh in Q1 FY26.
  • · Consolidated finance costs for Q1 FY27 were ₹7,100 lakh, up from ₹5,485 lakh in Q1 FY26.
  • · Consolidated employee benefits expense for Q1 FY27 was ₹38,818 lakh, up from ₹33,807 lakh in Q1 FY26.
  • · Consolidated professional and consultancy fee for Q1 FY27 was ₹52,343 lakh, up from ₹42,639 lakh in Q1 FY26.
  • · Consolidated other expenses for Q1 FY27 were ₹34,273 lakh, up from ₹29,496 lakh in Q1 FY26.
  • · Consolidated depreciation and amortization for Q1 FY27 was ₹13,166 lakh, up from ₹10,414 lakh in Q1 FY26.
  • · Consolidated tax expense for Q1 FY27 was ₹11,335 lakh, up from ₹9,246 lakh in Q1 FY26.
  • · Standalone finance costs for Q1 FY27 were ₹1,207 lakh, up from ₹925 lakh in Q1 FY26.
  • · Standalone other income for Q1 FY27 was ₹9,210 lakh, up from ₹7,985 lakh in Q1 FY26.
  • · Standalone tax expense for Q1 FY27 was ₹5,831 lakh, up from ₹5,685 lakh in Q1 FY26.
  • · The company acquired a 58.26% stake in Kalinga Hospital Ltd for ₹29,787 lakh, effective May 18, 2026.
  • · The company acquired 100% Class A shares of Yerawada Properties Private Limited for ₹68,792 lakh, effective June 30, 2026.
  • · MHC Global Healthcare (Nigeria) Limited is undergoing voluntary liquidation and will be deemed dissolved three months after July 29, 2026.
  • · Exceptional items in FY26 included ₹3,390 lakh for New Labour Codes impact and ₹1,434 lakh for stamp duty provision on merger (consolidated).
  • · The company granted 2,15,000 stock options under MHIL ESOP 2022 on May 20, 2026, with exercise price ₹350 to ₹600 per share.
  • · As of June 30, 2026, 80,66,242 stock options were outstanding under MHIL ESOP 2022.
  • · During Q1 FY27, the company allotted 1,08,748 ordinary shares of ₹10 each under its ESOP scheme.
  • · The statutory auditors issued an unmodified review report on both consolidated and standalone results.
  • · The consolidated results include three subsidiaries with total revenues of ₹1,881 lakh and net profit of ₹61 lakh, and three subsidiaries with net loss of ₹330 lakh (unreviewed).
Apollo Hospitals Enterprise Limited Company Update neutral materiality 1/10

14-08-2026

Apollo Hospitals Enterprise Limited has informed the stock exchanges that the audio recording of its analyst call for the financial results for the quarter ended June 30, 2026 is now available on the company's website. This is a routine disclosure under SEBI Listing Regulations and does not contain any financial results or performance data.

  • · The audio recording link is https://www.apollohospitals.com/sites/default/files/2026-08/10045185.mp3
  • · The filing is dated August 13, 2026 and was submitted to both BSE and NSE
IPCA Laboratories Limited Market Update positive materiality 8/10

13-08-2026

Ipca Laboratories reported strong Q1 FY27 results with standalone revenue from operations up 21% YoY to ₹2,119.24 Cr and consolidated revenue up 21% to ₹2,788.10 Cr. Standalone net profit surged 42% YoY to ₹373.29 Cr, while consolidated net profit jumped 80% to ₹422.81 Cr. However, other income declined 30% on a standalone basis and 23% on a consolidated basis, and the company recorded an exceptional item of ₹30.42 Cr in the prior quarter related to new Labour Codes.

  • · Standalone EBITDA margin improved to 26.27% in Q1 FY27 from 23.82% in Q1 FY26.
  • · Consolidated EBITDA margin improved to 22.88% in Q1 FY27 from 18.39% in Q1 FY26.
  • · Standalone export income grew 34% YoY to ₹935.39 Cr.
  • · Domestic formulations income grew 13% YoY to ₹1,082.12 Cr.
  • · API exports grew 33% YoY to ₹332.35 Cr.
  • · Institutional exports more than doubled, up 107% YoY to ₹119.75 Cr.
  • · The Board approved amalgamation of Krebs Biochemicals & Industries Ltd. with appointed date April 1, 2026, pending approvals.
  • · Exceptional items in prior periods included ₹30.42 Cr (standalone) and ₹45.82 Cr (consolidated) for new Labour Codes impact, and ₹58.26 Cr interest settlement with European Commission.
  • · Unichem Laboratories sold land and building for ₹279 Cr, recording a net gain of ₹17.65 Cr.
  • · The Group has one operating segment: Pharmaceuticals.
  • · Statutory auditors issued unmodified review reports for both standalone and consolidated results.
Max Healthcare Institute Limited Corporate Governance mixed materiality 8/10

13-08-2026

Max Healthcare Institute Limited's Board approved unaudited consolidated financial results for Q1 FY26 (quarter ended June 30, 2026). Revenue from operations grew ~10% YoY to ₹2,36,617 Lakhs, while profit after tax increased ~5% YoY to ₹32,296 Lakhs. However, on a sequential basis (vs Q4 FY26), revenue declined ~7% and PAT fell ~5%. The Board also approved a ~₹425 Crore capital expenditure for a new hospital tower in Vaishali, appointed two senior management personnel (Mr. Ajay Vij and Mr. Pawan Kumar Marella), and noted the resignation of Dr. N. Venkatesan.

  • · The company added two subsidiaries during FY26: Kalinga Hospital Limited (w.e.f. May 18, 2026) and Yerawada Properties Private Limited (w.e.f. June 30, 2026).
  • · Resignation of Dr. N. Venkatesan, Senior Director & Chief Procurement Officer, effective August 31, 2026.
  • · Total comprehensive income for Q1 FY26 was ₹31,815 Lakhs vs ₹34,347 Lakhs in Q1 FY25 (decline of ~7.4% YoY) and ₹30,516 Lakhs in Q4 FY26.
  • · Basic EPS for Q1 FY26 was ₹3.32 vs ₹3.52 in Q1 FY25 and ₹3.17 in Q4 FY26.
  • · Employee benefits expense increased to ₹38,818 Lakhs from ₹34,027 Lakhs (Q1 FY25) — up 14% YoY.
  • · Three subsidiaries with nil revenues reported net loss of ₹330 Lakhs for Q1 FY26.
Max Healthcare Institute Limited Market Notice mixed materiality 8/10

13-08-2026

Max Healthcare Institute reported Q1 FY27 gross revenue of ₹2,982 Cr, up 16% YoY, and Network Operating EBITDA of ₹704 Cr, up 15% YoY. However, PAT grew only 3% YoY to ₹357 Cr (down 8% QoQ), and EBITDA margin contracted to 24.8% from 24.9% YoY and 26.8% in Q4 FY26. The company completed two strategic acquisitions (Kalinga Hospital and Yerawada Properties) and approved ₹425 Cr capex for a brownfield tower at MSSH Vaishali.

  • · International patient revenue grew 18% YoY to ₹247 Cr, accounting for ~9% of hospital revenue.
  • · Max Lab revenue grew 20% YoY and 11% QoQ to ₹58 Cr, available across 60+ cities with 2,700+ tests.
  • · Max@Home revenue grew 32% YoY and 7% QoQ to ₹78 Cr.
  • · Net debt increased to ₹2,384 Cr from ₹1,908 Cr at end of March 2026, partly due to acquisitions.
  • · Free cash from operations declined 31.7% QoQ to ₹397 Cr from ₹581 Cr in Q4 FY26.
  • · EBITDA margin contracted to 24.8% from 24.9% YoY and 26.8% in Q4 FY26.
  • · MSSH Bhubaneswar (Kalinga Hospital) contributed ₹19 Cr revenue and ~₹2 Cr EBITDA in post-acquisition period, with 50% occupancy and ARPOB of ₹35k.
  • · 202 beds at Max Smart Super Speciality Hospital brownfield tower operationalized; remaining 198 beds to be handed over in Q2 FY27.
  • · Board approved ₹425 Cr capex for 202-bed brownfield tower at MSSH Vaishali, expected commissioning in Q4 FY30.
  • · Board granted in-principle approval to foray into medical education and set up medical colleges.
  • · Published 123 articles in high impact journals; 120 clinical trials and 25 grant studies ongoing.
  • · 610+ MBBS doctors in DNB programmes across 40 specialities; 1,000+ new students enrolled in online courses.
Aurobindo Pharma Limited Merger/Acquisition neutral materiality 3/10

13-08-2026

Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Auropharm Overseas Limited, in India on August 13, 2026. The subsidiary will undertake manufacturing and marketing operations in India and foreign countries. The initial subscription to the share capital is ₹10,00,000 (1,00,000 equity shares of ₹10 each), and no governmental or regulatory approvals were required.

  • · The subsidiary is incorporated as a wholly owned subsidiary, making it a related party of the company; promoters and promoter group have no interest in the transaction.
  • · The subsidiary's business is in the pharmaceuticals industry.
  • · No governmental or regulatory approvals were required for the incorporation.
  • · The subsidiary was incorporated on August 13, 2026, in India.
Dr. Reddy's Laboratories Limited Market Notice neutral materiality 4/10

13-08-2026

Dr. Reddy's Laboratories announced the resignation of Mr. Deepak Sapra, CEO of API and Services and Senior Management Personnel, effective November 12, 2026, to pursue opportunities outside the company. The change is a senior-level departure but does not include any financial impact or performance data.

  • · Mr. Deepak Sapra's resignation is effective from the close of business hours on November 12, 2026.
  • · The resignation is to pursue opportunities outside the company.
  • · No replacement or interim arrangement has been announced.
Abbott India Limited Corporate Governance neutral materiality 1/10

13-08-2026

The filing confirms the outcome of Abbott India Ltd's 82nd Annual General Meeting (AGM) held on August 13, 2026. The filing does not disclose any leadership changes, financial results, dividend recommendations, or strategic corporate actions. No specific quantitative data, period-over-period comparisons, or scheduled future events were provided beyond the AGM outcome itself. The filing is purely procedural, with no material governance or financial information to assess.

IPCA Laboratories Limited Corporate Governance neutral materiality 3/10

13-08-2026

Ipca Laboratories Limited held its 76th Annual General Meeting on August 13, 2026 via video conferencing. The meeting covered adoption of audited financial statements for FY ended March 31, 2026, declaration of dividend, re-appointment of directors, and ratification of cost auditor remuneration. No adverse auditor remarks or significant shareholder queries were reported.

  • · Meeting held via Video Conferencing / Other Audio Visual Means (VC/OAVM) at 3:30 PM IST.
  • · E-voting was conducted from August 10 to August 12, 2026, with the cut-off date for voting eligibility being August 7, 2026.
  • · Agenda included adoption of standalone and consolidated audited financial statements for FY ended March 31, 2026, dividend declaration, re-appointment of Ajit Kumar Jain and Pranay Godha as directors, re-appointment of Prashant Godha as Executive Director with remuneration, and ratification of cost auditor remuneration.
  • · No qualifications, adverse remarks, or observations in the Independent Auditors' Report.
  • · Meeting concluded at 4:15 PM IST.
Aurobindo Pharma Limited Analyst/Investor Meet positive materiality 8/10

13-08-2026

Aurobindo Pharma reported Q1 FY27 consolidated revenues of Rs. 9,150 crore, up 16% YoY, with operating EBITDA (excluding one-time impact) at Rs. 1,924 crore (21% margin). The company completed the Lannett acquisition, doubled China OSD production, and reiterated FY27 guidance of double-digit revenue growth with EBITDA margins above 21%. However, ARV formulation revenue remained flat at $35 million, and the net tax rate was elevated at 31.9% due to not taking tax credits on loss-making subsidiaries.

  • · Formulation business contributed approximately 89% of consolidated revenues.
  • · API business accounted for 11% of overall revenues.
  • · US business launched 10 new products, filed 9 ANDAs, and received 10 final approvals.
  • · European business grew 11% YoY in constant currency terms.
  • · Gross margin improved to 60.4% from 58.8% in Q1 FY26.
  • · Net CapEx for the quarter was $78 million, mainly towards TheraNym Biologics.
  • · R&D expenses were around Rs. 350 crore, 4% of revenues.
  • · Net cash position was $42 million after paying $85 million for buyback and $247 million for Lannett acquisition.
  • · Average finance cost declined to 4.8% from 5% in the previous quarter.
  • · Net effective tax rate was 31.9% due to not taking tax credit on loss-making subsidiaries; expected to normalize to 28-29% by year-end.
  • · Profit after tax stood at Rs. 1,032 crore.
  • · FY27 guidance: double-digit revenue growth, EBITDA margins north of 21%, absolute EBITDA in excess of Rs. 8,000 crore.
  • · Advair launch expected in August 2026.
  • · PEN-G plant producing 800-900 tonnes per month, converted into 6-APA and then Amoxi.
  • · China OSD facility production doubled over past 12 months.
  • · Growth markets expansion into Indonesia, China, and Canada.
Glenmark Pharmaceuticals Limited Market Notice neutral materiality 2/10

13-08-2026

Glenmark Pharmaceuticals has issued the notice for its 48th Annual General Meeting (AGM) to be held on September 11, 2026, via video conferencing. The agenda includes the adoption of audited financial statements for FY 2025-26, a proposed dividend of INR 2.50 per equity share, the re-appointment of Non-Executive Director Blanche Saldanha, and the ratification of the cost auditor's remuneration. The filing is a routine procedural disclosure with no financial performance data or period-over-period comparisons.

  • · The AGM will be held on Friday, September 11, 2026, at 2:00 PM IST via VC/OAVM.
  • · The dividend record date is Monday, August 31, 2026.
  • · Remote e-voting runs from September 8, 2026 (9:00 AM) to September 10, 2026 (5:00 PM).
  • · The dividend, if approved, will be paid on or after September 14, 2026.
  • · The company has dispensed with physical attendance and proxy facility for this AGM.
  • · A special resolution is proposed for the re-appointment of Mrs. Blanche Saldanha, aged 86, as a Non-Executive Director.
Glenmark Pharmaceuticals Limited Market Notice neutral materiality 3/10

13-08-2026

Glenmark Pharmaceuticals has issued the notice for its 48th Annual General Meeting (AGM) to be held on September 11, 2026, via video conferencing, and has published its Integrated Annual Report for FY 2025-26. The board has recommended a dividend of INR 2.50 per equity share for the financial year ended March 31, 2026. The AGM will also seek approval for the re-appointment of Non-Executive Director Blanche Saldanha and ratification of the cost auditor's remuneration.

  • · The AGM will be held on Friday, September 11, 2026, at 2:00 PM IST via VC/OAVM.
  • · The dividend record date is Monday, August 31, 2026.
  • · The cut-off date for e-Voting is Friday, September 4, 2026.
  • · Remote e-Voting runs from Tuesday, September 8, 2026 (9:00 AM) to Thursday, September 10, 2026 (5:00 PM).
  • · e-Voting results will be announced on or before Tuesday, September 15, 2026.
  • · The dividend, if approved, will be paid on or after Monday, September 14, 2026.
  • · The company has dispensed with physical attendance and proxy appointments for this AGM.
  • · The re-appointment of Mrs. Blanche Saldanha (aged 86) as a Non-Executive Director is proposed as a Special Resolution.
  • · The cost auditor's remuneration of INR 2.8 million for FY 2026-27 is proposed for ratification as an Ordinary Resolution.
Max Healthcare Institute Limited Market Update neutral materiality 2/10

13-08-2026

Max Healthcare Institute Limited has granted a total of 3,61,827 stock options to eligible employees under its Employee Stock Option Scheme 2022, as approved by the Nomination and Remuneration Committee on August 13, 2026. The grant comprises two tranches: 1,61,827 options at an exercise price of ₹800 per option and 2,00,000 options at an exercise price of ₹350 per option. This is a routine employee incentive disclosure with no financial impact reported.

  • · The Nomination and Remuneration Committee meeting commenced at 7:50 AM IST and concluded at 8:20 AM IST on August 13, 2026.
  • · Each stock option is convertible into one fully paid-up equity share with a face value of ₹10.
  • · Vesting period: not earlier than 1 year and not later than 5 years from the date of grant, subject to pre-vesting conditions.
  • · Exercise period: 3 years from the respective date of vesting.
GlaxoSmithKline Pharmaceuticals Limited Corporate Governance neutral materiality 3/10

13-08-2026

GlaxoSmithKline Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director for a two-year term from 1st December 2026 to 30th November 2028. The e-voting period runs from 14th August 2026 to 13th September 2026, with results announced on or before 15th September 2026. No financial figures or performance metrics are disclosed in this filing.

  • · Ms. Karine J F Natland was appointed as an Additional Director with effect from 4th August 2026 and is now proposed for appointment as a Non-Executive Director, liable to retire by rotation.
  • · Mr. Bhushan Akshikar's re-appointment as Managing Director is for a period of two years from 1st December 2026 to 30th November 2028.
  • · The cut-off date for determining eligible shareholders is 7th August 2026.
  • · The Scrutinizer appointed is P.N. Parikh (FCS 327 and CP 1228), with Jigyasa Ved (FCS 6488 and CP 6018) as the alternate, from Parikh & Associates.

Get daily alerts with 10 investment signals, 8 risk alerts, 10 opportunities and full AI analysis of all 17 filings

Start free trial Browse all digests

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

August 11, 2026

BSE Pharma Sector Regulatory Filings — August 11, 2026

August 10, 2026

BSE Pharma Sector Regulatory Filings — August 10, 2026

August 08, 2026

BSE Pharma Sector Regulatory Filings — August 08, 2026

August 07, 2026

BSE Pharma Sector Regulatory Filings — August 07, 2026

🇮🇳 More from India

View all →

August 13, 2026

India Pre-Market Regulatory Roundup — August 13, 2026

India Pre-Market Regulatory Roundup

August 13, 2026

India AGM EGM Shareholder Meeting Schedule — August 13, 2026

India AGM EGM Shareholder Meeting Schedule

August 13, 2026

India Quarterly Results BSE NSE Announcements — August 13, 2026

India Quarterly Results BSE NSE Announcements

August 13, 2026

India Upcoming Corporate Actions BSE NSE — August 13, 2026

India Upcoming Corporate Actions BSE NSE
← All India digests